您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > LT175
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LT175
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LT175图片
CAS NO:862901-87-9
规格:98%
分子量:318.4
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
dual PPARα/γ ligand
CAS:862901-87-9
分子式:C21H18O3
分子量:318.4
纯度:98%
存储:Store at -20°C

Background:

LT175 is a dual PPARα/γ ligand.


Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors regulating lipid and glucose metabolism.


In vitro: LT175 was identified as a partial agonist against PPARγ and interacted with a newly identified region of the PPARγ-ligand binding domain. LT175 could differentially activate PPARγ target genes involved in fatty acid esterification and storage, resulting in a less severe lipid accumulation compared with that triggered by rosiglitazone. Moreover, the peculiar interaction of LT175 with PPARγ could affect the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 [1].


In vivo: Animal in vivo study showed that the administration of LT175 to mice fed a high-fat diet could decrease the adipocyte size, body weight, as well as white adipose tissue mass, as measured by magnetic resonance imaging. In addition, LT175 was able to significantly reduce the insulin, plasma glucose, triglycerides, non-esterified fatty acids, and cholesterol and also could increase the levels of circulating adiponectin and fibroblast growth factor 21. Moreover, the oral glucose and insulin tolerance tests showed that LT175 could improve glucose homeostasis and insulin sensitivity [1].


Clinical trial: So far, no clinical study has been conducted.


Reference:
[1] Gilardi F et al.  LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. J Biol Chem. 2014 Mar 7;289(10):6908-20.